Quiz|Articles|November 2, 2025
Dermatology Times Spot Test: November 2, 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Chronic hand eczema involves inflammation, itching, and skin barrier dysfunction, often worsened by environmental and occupational factors.
- Advancements in CHE understanding have improved diagnostic criteria and treatment options, including topical and systemic therapies.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Advertisement
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we're focusing on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
In the DELTA FORCE head-to-head trial, delgocitinib was compared with which drug?
In this retrospective study, what percentage of patients taking daily isotretinoin developed CHE?
At Fall Clinical 2025, US prevalence data from LEO Pharma revealed that what percentage of adults attributed their CHE to work?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Improving Outcomes in Acne, Hidradenitis Suppurativa, and Vitiligo Through Treatment Advancements
2
Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years
3
Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline
4
Immune Signatures Outperform Clinical Appearance in Treatment Guidance
5
